The role of gut microbiota and metabolomic pathways in modulating the efficacy of SSRIs for major depressive disorder.
Level 3 - non-randomized controlled study
Prospective non-randomized cohort study evaluating biomarker differences between treatment responders and non-responders
PubMed 39695082 · doi:10.1038/s41398-024-03208-z
What was done
A prospective cohort study examined gut microbiota and metabolomic profiles in 126 patients with major depressive disorder undergoing SSRI treatment. Patients were classified as responders or non-responders based on changes in Hamilton Depression Rating Scale (HAMD-17) scores before and after treatment. Fecal samples were analyzed using 16S rRNA gene sequencing and metabolomics, and a predictive machine learning model was developed.
What was found
Gut microbiota composition differed significantly between responders and non-responders. The responder group showed greater relative abundance of taxa including Ruminococcus, Bifidobacterium, and Faecalibacterium, as well as upregulated acetate degradation and neurotransmitter synthesis pathways. The abstract provides no specific numerical values, effect sizes, p-values, or machine learning model performance metrics.
Why it matters
Identifying baseline or treatment-associated gut microbial and metabolic profiles could help clarify mechanisms of antidepressant response and identify candidate biomarkers for personalized depression treatment.
Limits
The abstract provides no quantitative data, effect estimates, or predictive accuracy metrics. The sample size is modest (n = 126), specific SSRI medications and treatment durations are not detailed, and the observational design cannot establish causal relationships.
Cited by
- context Selective serotonin reuptake inhibitors (SSRIs) exert their clinical therapeutic effects by altering the gut microbiome to a favorable tryptophan-pathway microbiome rather than by blocking brain serotonin reuptake.